drugset / Trial / NCT05454241
CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies
NaSingle-groupOpen-labelTreatment
Summary
This is a open-label, phase 2 study to evaluate the efficacy, safety and PK of CD7 chimeric antigen receptors treatment for patients with refractory/relapsed CD7 positive hematological malignancies.
Timeline
- Start
- 2022-09-07
- Primary completion
- 2024-08-31
- Completion
- 2024-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anti-CD7 CAR-T | Cell therapy | — | — |